Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen

Schizophrenia Clinical Trial

Official title:

Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): the Effects of D2 Antagonism on Candidate Endophenotypes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01555814
• Other study ID #: H-1-2010-142
• Status: Completed
• Phase: N/A
• First received: September 19, 2011
• Last updated: October 25, 2016
• Start date: May 2011
• Est. completion date: October 2016

Study information

• Verified date: October 2016
• Source: University of Copenhagen
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: Danish Dataprotection AgencyDenmark: The Regional Committee on Biomedical Research Ethics
• Study type: Interventional

Clinical Trial Summary

The investigators want to relate disturbances in first-episode schizophrenic patients in (dopaminergic) D2 receptors, brain structure, brain function, and information processing to each other and to psychopathology. Additionally, the investigators want to examine the influence of D2 receptor blockade on these disturbances. The investigators expect disturbances in the dopaminergic system at baseline to correlate with specific structural and functional changes and with disruption in information processing as measured with psychophysiological and neurocognitive methods - and investigators expect D2 receptor blockade to reverse some of the functional and cognitive impairments. The investigators do not expect any effect of treatment on brain structure.

Description:

The study is designed as a 4 week case-control follow-up study of 90 FE pt. with SCZ and 90 controls matched with regard to age, gender, and parental socio-economic status. All subjects will be examined with a diagnostic interview (SCAN, Schedule for Clinical Assessment in Neuropsychiatry), medical and family history, and physical examination before inclusion. At baseline subjects will be examined with single photon emission computed tomography (SPECT), MRI, fMRI, psychophysiology, neurocognition. In addition, they will be screened for drugs, genetic testing, and ECG. Patients will further be examined with clinical validated rating scales to measure psychopathology, subjective well-being, and side-effects. After a period of 4 weeks all assessments are repeated. During that period patients will be treated with amisulpride, while healthy controls will receive no treatment at all. Efficacy of antipsychotic treatment will be evaluated after this initial period of 4 weeks. All subjects will be re-assessed in the same test battery as mentioned above, except for SPECT and fMRI, after a period of 6, 12, and 24 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: October 2016
• Est. primary completion date: July 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Schizophrenia, schizophreniform or schizoaffective disorder (DSM-IV)

• Age 18-40 years

• Written informed consent.

Exclusion Criteria:

• A time interval between the onset of positive symptoms (hallucinations and/or delusions) and study entry exceeding two years.

• Prior use of antipsychotic medication longer than an episode of two weeks in the previous year and/or 6 weeks lifetime.

• Intolerance to one of the drugs in this study. Patients who are coercively treated at a psychiatric ward (based on a judicial ruling)

• Patients who are represented by a legal ward or under legal custody

• The presence of one or more of the contraindications against any of the study drugs as mentioned in the SPC texts

• Pregnancy, as determined through a pregnancy test, or lactation

Study Design

Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Disease
• Psychotic Disorders
• Schizoaffective Disorder
• Schizophrenia
• Schizophreniform Disorder

Intervention

Drug:
• Amisulpride
4-week open label amisulpride treatment

Locations

Country	Name	City	State
Denmark	Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup Glostrup, Denmark	Glostrup

Sponsors (6)

Lead Sponsor	Collaborator
Birte Glenthoj	Copenhagen Hospital Corporation, Glostrup University Hospital, Copenhagen, Institute of Psychiatry, London, Rigshospitalet, Denmark, UMC Utrecht

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relationship between specific neuropsychiatric measures and global improvement on PANSS scores	Changes in neuropsychiatric measures like (e.g. PPI, P50-suppression, neurocogtion etc.) will be evaluated and related to the primary outcome measure of the main OPTiMiSE study, the PANSS score change from baseline to follow-up.	4 weeks of medical treatment	No
Secondary	Effect of antipsychotic medication on the D2 binding potential (SPECT) in antipsychotic naive patients with schizophrenia.	D2 receptor binding will be evaluated at baseline and after 4 weeks of treatment. This will be related to measures of the human reward system.	Baseline, 4 weeks	No
Secondary	Effect of antipsychotic medication on P50-suppression	Time/dose improvement on P50 suppression after antipsychotic treatment	Baseline, 4 weeks, 6,12,24 months	No
Secondary	Effect of antipsychotic medication on the human reward system	Disturbances in the human reward system in antipsychotic naive patients with schizophrenia will be evaulated using a reward related BOLD fMRI paradigme.	Baseline and 4 weeks follow up	No
Secondary	Change in hippocampal and basal ganglia volume from baseline to follow-up.	Hippocampal volume decrease and basal ganglia volume increase is expected longitudinal outcomes.	4 weeks, 6, 12 and 24 months,	No
Secondary	Change in processing speed over time after antipsychotic treatment.	Processing speed is expected to improve.	Baseline, 4 weeks, 6,12,24 months	No
Secondary	Change in levels of brain perfusion from baseline to follow-up.	Brain perfusion levels will be measured in brain areas related to the human reward systems.	Baseline, 4 weeks treatment	No

External Links

•   Site home page